Standardization and quality control studies of 'real-time'quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease …
J Gabert, E Beillard, VHJ Van der Velden, W Bi… - Leukemia, 2003 - nature.com
Detection of minimal residual disease (MRD) has proven to provide independent prognostic
information for treatment stratification in several types of leukemias such as childhood acute …
information for treatment stratification in several types of leukemias such as childhood acute …
Basic principles of real-time quantitative PCR
M Arya, IS Shergill, M Williamson… - Expert review of …, 2005 - Taylor & Francis
Real-time quantitative PCR allows the sensitive, specific and reproducible quantitation of
nucleic acids. Since its introduction, real-time quantitative PCR has revolutionized the field …
nucleic acids. Since its introduction, real-time quantitative PCR has revolutionized the field …
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
N Gökbuget, H Dombret, M Bonifacio… - Blood, The Journal …, 2018 - ashpublications.org
Abstract Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in
hematologic complete remission after multiagent therapy exhibit minimal residual disease …
hematologic complete remission after multiagent therapy exhibit minimal residual disease …
Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
N Toft, H Birgens, J Abrahamsson, L Griškevičius… - Leukemia, 2018 - nature.com
Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …
12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1–45 years with …
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232
Minimal residual disease (MRD) is highly prognostic in pediatric B-precursor acute
lymphoblastic leukemia (B-ALL). In Children's Oncology Group high-risk B-ALL study …
lymphoblastic leukemia (B-ALL). In Children's Oncology Group high-risk B-ALL study …
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
J Martinez-Lopez, JJ Lahuerta, F Pepin… - Blood, The Journal …, 2014 - ashpublications.org
We assessed the prognostic value of minimal residual disease (MRD) detection in multiple
myeloma (MM) patients using a sequencing-based platform in bone marrow samples from …
myeloma (MM) patients using a sequencing-based platform in bone marrow samples from …
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR …
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
VHJ Van der Velden, G Cazzaniga, A Schrauder… - Leukemia, 2007 - nature.com
Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the
analysis of minimal residual disease (MRD). To ensure comparable MRD results between …
analysis of minimal residual disease (MRD). To ensure comparable MRD results between …
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
C Parker, R Waters, C Leighton, J Hancock, R Sutton… - The Lancet, 2010 - thelancet.com
Background Although survival of children with acute lymphoblastic leukaemia has improved
greatly in the past two decades, the outcome of those who relapse has remained static. We …
greatly in the past two decades, the outcome of those who relapse has remained static. We …
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
R Bassan, O Spinelli, E Oldani… - Blood, The Journal …, 2009 - ashpublications.org
Clinical risk classification is inaccurate in predicting relapse in adult patients with acute
lymphoblastic leukemia, sometimes resulting in patients receiving inappropriate …
lymphoblastic leukemia, sometimes resulting in patients receiving inappropriate …